Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Open Access
- 4 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (9), e1508-e1513
- https://doi.org/10.1002/onco.13810
Abstract
Lessons Learned Cemiplimab in combination with radiation therapy, cyclophosphamide, and granulocyte macrophage colony‐stimulating factor (GM‐CSF) did not demonstrate efficacy above what can be achieved with other PD‐1 inhibitor monotherapies in patients with Refractory and metastatic head and neck squamous cell carcinoma. The safety profile of cemiplimab combination therapy was consistent with previously reported safety profiles of cemiplimab monotherapy. No new safety signal was observed. Background Refractory and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) generally does not respond to PD‐1 inhibitor monotherapy. Cemiplimab is a human anti‐PD‐1 monoclonal antibody. An expansion cohort enrolled patients with R/M HNSCC in a phase I study combining cemiplimab plus radiation therapy (RT), cyclophosphamide, and granulocyte macrophage colony‐stimulating factor (GM‐CSF). Methods Patients with R/M HNSCC refractory to at least first‐line therapy and for whom palliative RT is clinically indicated received cemiplimab plus RT, cyclophosphamide, and GM‐CSF. The co‐primary objectives were the safety, tolerability, and efficacy of cemiplimab plus RT, cyclophosphamide and GM‐CSF in 15 patients (pts) with R/M HNSCC. Results Fifteen patients were enrolled. Patients discontinued treatment due to progression of disease. The most common treatment‐emergent adverse events (TEAEs) of any grade (Gr) were fatigue (40.0%), constipation (26.7%), and asthenia, dyspnea, maculo‐papular rash, and pneumonia (each 20%). The only Gr ≥3 TEAE that occurred in 2 pts was pneumonia (13.3%). By investigator‐assessment, there was 1 partial response (6.7%); disease control rate was 40.0% (95% CI: 16.3–67.7; 5 with stable disease); 7 patients had progressive disease and 2 were not evaluable. Median progression‐free survival by investigator‐assessment was 1.8 months (95% CI: 1.7–4.7). Conclusion The regimen demonstrated tolerability but not efficacy above that which can be achieved with anti‐PD‐1 inhibitor monotherapy for R/M HNSCC.Keywords
This publication has 16 references indexed in Scilit:
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2016
- Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trialThe Lancet Oncology, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neckCancer Chemotherapy and Pharmacology, 2014
- Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironmentOncoImmunology, 2013
- Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast CancerClinical Cancer Research, 2012
- The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in diseaseBlood, 2009
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck CancerThe New England Journal of Medicine, 2004